TD Cowen starts coverage with a USD 55 target for Teva stock
Published on 10/08/2026 at 13:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Teva Pharmaceutical Industries (ISIN US8816242098) received a USD 55.00 price target and Buy rating from TD Cowen on October 1, 2026. The coverage puts Teva's generic and biosimilar base alongside its growing specialty medicines pipeline, giving the analyst view a direct operating rationale.
TD Cowen backs the pipeline
According to Investing.com on October 1, 2026, TD Cowen analyst Joseph Thome initiated coverage with a Buy rating and a USD 55.00 target. The report highlighted approved products in neuropsychiatry and central nervous system treatments, while also pointing to potential launches including ecopipam and olanzapine long-acting injectable therapy.
The same report named duvakitug, TEV-408 and DARI as pipeline assets supporting the valuation view. That combination matters because Teva is being assessed not only as a generic-drug manufacturer but also as a company with branded and specialty growth options.
Revenue remains the counterweight
Teva's second-quarter 2026 revenue was USD 4.14 billion, according to MarketBeat. That figure compares with USD 4.18 billion in the year-earlier quarter, a decline of 0.96 percent and a reminder that pipeline value must be converted into commercial growth.
The earnings calendar shown for Teva points to November 3, 2026, for the next report. That date gives the market a concrete checkpoint for testing whether newer products can offset pressure on the established portfolio.
Stock stays near its yearly high
Teva was last at USD 39.18 on the NYSE on October 7, 2026 at 4:00 p.m. ET. Its 52-week range was USD 18.83 to USD 40.79, leaving the stock 3.95 percent below the high and placing the current level near the top of its yearly band.
Market capitalization stood at USD 45.6 billion as of October 7, 2026. For investors, the key tension is visible in the numbers: TD Cowen values the pipeline at USD 55.00 per share, while second-quarter revenue remained below the year-earlier USD 4.18 billion.
November results set the next test
Teva's next scheduled reporting date is November 3, 2026, while the USD 55.00 TD Cowen target and the USD 39.18 NYSE quote frame the current valuation debate. The stock's position 3.95 percent below its 52-week high leaves execution on revenue growth as the central near-term question.
The further course of trading is shown by the continuously updated real-time quote of Teva stock.
Teva stock at a glance
- Company: Teva Pharmaceutical Industries Limited
- ISIN: US8816242098
- Ticker: TEVA
- Primary exchange: NYSE
- Market capitalization: USD 45.6 billion (as of October 7, 2026)
- 52-week range: USD 18.83-USD 40.79 (as of October 7, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
